Diclofenac (Voltaren) is Superior to Gabapentin for Low Back Pain with Sciatica
For an adult with low back pain and sciatica, diclofenac (Voltaren) is the preferred medication over gabapentin. NSAIDs like diclofenac have established efficacy for radicular low back pain, while gabapentin lacks convincing evidence for this indication and carries significant adverse event risks.
Evidence-Based Rationale
Why Diclofenac is Preferred
The most recent American College of Physicians guideline evidence (2017) found that NSAIDs demonstrate consistent effectiveness for low back pain, with small to moderate pain relief effects 1. While the 2007 ACP/APS guideline noted only "fair evidence" for gabapentin specifically in radiculopathy 2, this limited support has been contradicted by more recent high-quality research.
NSAIDs work through direct anti-inflammatory mechanisms that target the underlying pathophysiology of sciatica—nerve root inflammation from disc herniation or spinal stenosis. Diclofenac specifically inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis and subsequent inflammation 3.
Why Gabapentin Should Be Avoided
The evidence against gabapentin for sciatica is compelling:
A 2022 systematic review and meta-analysis specifically examining gabapentin and pregabalin for sciatica found "clear evidence for lack of effectiveness" and concluded "its routine clinical use cannot be supported" 4
A 2018 systematic review with high-quality evidence demonstrated gabapentin was ineffective for lumbar radicular pain in both immediate and short-term follow-up (pooled MD -0.1,95% CI -0.7 to 0.5), while simultaneously showing high-quality evidence of increased adverse event risk 5
The 2017 guideline update noted that evidence remains insufficient to determine the effects of antiseizure medications for low back pain 1
Safety Considerations
Gabapentin carries substantial adverse event burden including somnolence, dizziness, peripheral edema, ataxia, and thinking abnormalities—occurring in 21-28% of patients for somnolence and dizziness alone 6. These central nervous system effects can significantly impair function and quality of life, potentially worsening disability beyond the sciatica itself.
In contrast, NSAIDs show no increased risk of adverse events compared to placebo in acute settings (RR 0.86,95% CI 0.63 to 1.18) 7, and low-certainty evidence suggests no increased risk in chronic use (RR 1.04,95% CI 0.92 to 1.17) 7.
Clinical Algorithm
Start with diclofenac:
- Oral: 50 mg three times daily or 75 mg twice daily
- Duration: 5-14 days for acute sciatica
- Monitor for gastrointestinal symptoms and cardiovascular risk factors
Gabapentin should only be considered if:
- NSAIDs are contraindicated (active peptic ulcer, severe renal impairment, cardiovascular disease)
- Patient has failed adequate NSAID trial
- Even then, evidence suggests it likely won't work
Do not combine both medications initially—there is no evidence supporting additive benefit, and you simply increase adverse event exposure 8.
Common Pitfalls
Prescribing gabapentin based on the "neuropathic pain" label: While sciatica involves nerve root irritation, it responds differently than diabetic neuropathy or postherpetic neuralgia where gabapentin has proven efficacy
Assuming gabapentin is "safer" than NSAIDs: The adverse event profile of gabapentin (sedation, dizziness, cognitive effects) can be more functionally impairing than NSAID gastrointestinal risks in most patients
Using topical diclofenac for sciatica: Recent evidence shows topical diclofenac is less efficacious than oral ibuprofen for acute low back pain (between-group difference 3.7,95% CI 0.2 to 7.2) 9
Prolonged courses without reassessment: If sciatica persists beyond 2-4 weeks on NSAIDs, the issue is not medication choice but rather need for imaging and possible interventional or surgical evaluation
The evidence hierarchy clearly favors NSAIDs like diclofenac as first-line pharmacotherapy for sciatica, with gabapentin lacking both efficacy data and carrying unacceptable adverse event burden for this indication 1, 4, 5.